Compare Steel Dynamics Inc. (STLD) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Steel Dynamics Inc. vs Tango Therapeutics Inc. — how do they compare? Steel Dynamics Inc. trades at $244.39 (market cap $34.49B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: Steel Dynamics Inc. is far larger — about 9.2× Tango Therapeutics Inc.'s market cap, and Steel Dynamics Inc. pays a 0.88% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Steel Dynamics Inc. for 6 Days and Tango Therapeutics Inc. for 0 Days on average.
| STLD | TNGX | |
|---|---|---|
Market Cap | $34.49B | $3.75B |
Volume | 688,362 | 9,619,106 |
Sector | Basic Materials | Health |
52-Week High | $282.76 | $32.90 |
52-Week Low | $142.65 | $7.50 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $38.10B | $2.77B |
Dividend Yield | 0.88% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Steel Dynamics (STLD) trades at $240.63, up 0.62% on the day, with a neutral technical signal and bullish moving averages. The stock shows strong fundamentals, including a 7.83% net income margin and 17.58% ROE, with Q3 2026 earnings expected at $5.41 EPS. Recent news highlights anticipation for the upcoming earnings report on October 19, 2026.
The outlook is positive, supported by analyst consensus of a $271.17 price target and 'Moderate Buy' ratings. Risks include earnings volatility and steel market cyclicality, but revenue growth to $20.5B in 2026 and solid cash flow provide a foundation for potential upside.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Steel Dynamics Inc.
Steel Dynamics produces steel, processes recycled metals, and provides steel-fabrication services. Its operations use recycled scrap as a key input and also include aluminum products.
Read more on STLD →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
